Jennifer Diamond
Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Triple Negative Breast Neoplasms | 16 | 2024 | 191 | 6.660 |
Why?
| Breast Neoplasms | 23 | 2023 | 2132 | 4.380 |
Why?
| Immunoconjugates | 7 | 2023 | 101 | 2.600 |
Why?
| Antineoplastic Agents | 23 | 2023 | 2051 | 2.600 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2023 | 1559 | 2.460 |
Why?
| Pyrimidines | 9 | 2021 | 445 | 2.400 |
Why?
| Receptor, ErbB-2 | 11 | 2023 | 325 | 1.950 |
Why?
| Protein Kinase Inhibitors | 10 | 2022 | 872 | 1.730 |
Why?
| Piperazines | 4 | 2020 | 336 | 1.700 |
Why?
| Paclitaxel | 6 | 2022 | 214 | 1.620 |
Why?
| Camptothecin | 9 | 2023 | 106 | 1.600 |
Why?
| Neoplasms | 14 | 2022 | 2464 | 1.600 |
Why?
| Pyrazoles | 6 | 2021 | 404 | 1.390 |
Why?
| Quinoxalines | 2 | 2020 | 65 | 1.310 |
Why?
| Antibodies, Monoclonal, Humanized | 10 | 2024 | 755 | 1.290 |
Why?
| Azepines | 3 | 2020 | 88 | 1.250 |
Why?
| Ovarian Neoplasms | 4 | 2020 | 488 | 1.220 |
Why?
| Histone Deacetylase Inhibitors | 4 | 2024 | 207 | 1.210 |
Why?
| Cyclin-Dependent Kinase 4 | 2 | 2018 | 42 | 1.110 |
Why?
| Cyclin-Dependent Kinase 6 | 2 | 2018 | 39 | 1.100 |
Why?
| Neutropenia | 4 | 2022 | 134 | 0.890 |
Why?
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 1351 | 0.790 |
Why?
| Xenograft Model Antitumor Assays | 11 | 2021 | 814 | 0.760 |
Why?
| beta Catenin | 2 | 2020 | 219 | 0.760 |
Why?
| Breast Neoplasms, Male | 2 | 2018 | 29 | 0.740 |
Why?
| Female | 49 | 2024 | 68154 | 0.700 |
Why?
| Cancer Care Facilities | 1 | 2020 | 32 | 0.690 |
Why?
| Chemotherapy, Adjuvant | 4 | 2023 | 376 | 0.690 |
Why?
| Maximum Tolerated Dose | 9 | 2022 | 192 | 0.690 |
Why?
| Benzoxazoles | 1 | 2020 | 19 | 0.690 |
Why?
| Receptors, Estrogen | 3 | 2021 | 424 | 0.680 |
Why?
| Carcinoma, Lobular | 2 | 2018 | 48 | 0.680 |
Why?
| eIF-2 Kinase | 1 | 2019 | 29 | 0.650 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 210 | 0.640 |
Why?
| Tumor Microenvironment | 4 | 2024 | 623 | 0.630 |
Why?
| Anthracyclines | 3 | 2023 | 46 | 0.610 |
Why?
| Humans | 62 | 2024 | 128418 | 0.610 |
Why?
| Taxoids | 3 | 2023 | 95 | 0.600 |
Why?
| Drug Resistance, Neoplasm | 4 | 2020 | 749 | 0.580 |
Why?
| Wnt Signaling Pathway | 1 | 2019 | 165 | 0.580 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2018 | 82 | 0.570 |
Why?
| Aurora Kinase A | 4 | 2020 | 55 | 0.570 |
Why?
| Aged | 22 | 2023 | 21953 | 0.560 |
Why?
| Trastuzumab | 4 | 2023 | 100 | 0.560 |
Why?
| Pyrazines | 2 | 2018 | 86 | 0.540 |
Why?
| Myocardial Infarction | 1 | 2023 | 1015 | 0.520 |
Why?
| Colonic Neoplasms | 1 | 2018 | 242 | 0.510 |
Why?
| Pyridines | 2 | 2018 | 475 | 0.510 |
Why?
| Tumor Suppressor Protein p53 | 4 | 2024 | 508 | 0.500 |
Why?
| Neoadjuvant Therapy | 1 | 2018 | 381 | 0.490 |
Why?
| Nuclear Proteins | 2 | 2023 | 657 | 0.490 |
Why?
| Angiopoietin-1 | 1 | 2015 | 11 | 0.490 |
Why?
| Angiopoietin-2 | 1 | 2015 | 15 | 0.490 |
Why?
| Medicare | 4 | 2023 | 715 | 0.450 |
Why?
| Uterine Cervical Neoplasms | 1 | 2017 | 232 | 0.450 |
Why?
| Cell Line, Tumor | 9 | 2022 | 3184 | 0.440 |
Why?
| Colorectal Neoplasms | 5 | 2022 | 746 | 0.430 |
Why?
| Middle Aged | 23 | 2021 | 30889 | 0.420 |
Why?
| Antibodies, Monoclonal | 4 | 2024 | 1355 | 0.410 |
Why?
| Dose-Response Relationship, Drug | 6 | 2022 | 1936 | 0.410 |
Why?
| Cell Proliferation | 8 | 2020 | 2344 | 0.400 |
Why?
| Tumor Suppressor Proteins | 1 | 2015 | 313 | 0.400 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2013 | 74 | 0.400 |
Why?
| Antineoplastic Agents, Immunological | 3 | 2019 | 175 | 0.400 |
Why?
| Recombinant Fusion Proteins | 1 | 2015 | 634 | 0.390 |
Why?
| Point Mutation | 1 | 2013 | 223 | 0.390 |
Why?
| Adult | 24 | 2024 | 35300 | 0.390 |
Why?
| Treatment Outcome | 12 | 2022 | 10152 | 0.390 |
Why?
| Triazoles | 1 | 2013 | 147 | 0.380 |
Why?
| Angiogenesis Inhibitors | 3 | 2018 | 215 | 0.370 |
Why?
| Mice, Nude | 6 | 2020 | 682 | 0.360 |
Why?
| Carcinoma, Renal Cell | 1 | 2013 | 179 | 0.360 |
Why?
| Mitochondria | 1 | 2017 | 848 | 0.350 |
Why?
| Clinical Trials, Phase I as Topic | 2 | 2020 | 50 | 0.350 |
Why?
| Neoplasm Recurrence, Local | 4 | 2021 | 958 | 0.340 |
Why?
| Heart Failure | 1 | 2023 | 2145 | 0.340 |
Why?
| Histones | 3 | 2023 | 586 | 0.340 |
Why?
| Neoplasm Metastasis | 4 | 2020 | 608 | 0.340 |
Why?
| Genes, BRCA2 | 1 | 2009 | 24 | 0.330 |
Why?
| Genes, BRCA1 | 1 | 2009 | 32 | 0.330 |
Why?
| Biomarkers, Tumor | 2 | 2014 | 1181 | 0.330 |
Why?
| Molecular Targeted Therapy | 3 | 2019 | 385 | 0.320 |
Why?
| Aged, 80 and over | 8 | 2020 | 7033 | 0.320 |
Why?
| BRCA2 Protein | 1 | 2009 | 53 | 0.320 |
Why?
| Thrombophilia | 1 | 2009 | 66 | 0.310 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 2009 | 52 | 0.310 |
Why?
| Neoplasm Staging | 5 | 2021 | 1290 | 0.310 |
Why?
| Lung Neoplasms | 2 | 2024 | 2328 | 0.310 |
Why?
| Kidney Neoplasms | 1 | 2013 | 349 | 0.310 |
Why?
| Apoptosis | 7 | 2024 | 2435 | 0.310 |
Why?
| Quinolines | 2 | 2021 | 153 | 0.300 |
Why?
| Aromatase Inhibitors | 2 | 2018 | 51 | 0.300 |
Why?
| Receptors, Progesterone | 2 | 2021 | 341 | 0.290 |
Why?
| DNA-Binding Proteins | 1 | 2015 | 1421 | 0.280 |
Why?
| Mice | 9 | 2021 | 16602 | 0.270 |
Why?
| Models, Biological | 1 | 2014 | 1691 | 0.260 |
Why?
| Doxorubicin | 3 | 2024 | 322 | 0.250 |
Why?
| Liver Neoplasms | 1 | 2009 | 633 | 0.220 |
Why?
| Cyclophosphamide | 2 | 2018 | 227 | 0.220 |
Why?
| Radiosurgery | 2 | 2019 | 318 | 0.220 |
Why?
| Disease Models, Animal | 3 | 2021 | 3937 | 0.220 |
Why?
| United States | 5 | 2023 | 13830 | 0.210 |
Why?
| Animals | 11 | 2021 | 34479 | 0.200 |
Why?
| Cyclin-Dependent Kinase 9 | 1 | 2022 | 10 | 0.200 |
Why?
| Biopsy | 2 | 2018 | 1081 | 0.200 |
Why?
| Histone Deacetylase 1 | 1 | 2022 | 24 | 0.190 |
Why?
| Administration, Oral | 3 | 2022 | 754 | 0.190 |
Why?
| Aurora Kinases | 2 | 2012 | 29 | 0.190 |
Why?
| G2 Phase Cell Cycle Checkpoints | 3 | 2022 | 45 | 0.190 |
Why?
| Disease Progression | 4 | 2019 | 2602 | 0.190 |
Why?
| Topoisomerase I Inhibitors | 2 | 2022 | 16 | 0.190 |
Why?
| Fluorouracil | 1 | 2022 | 197 | 0.190 |
Why?
| Acetylation | 1 | 2022 | 237 | 0.180 |
Why?
| Biliary Tract Neoplasms | 1 | 2021 | 25 | 0.180 |
Why?
| Arrhythmias, Cardiac | 1 | 2023 | 316 | 0.180 |
Why?
| Androstadienes | 1 | 2021 | 106 | 0.180 |
Why?
| Diarrhea | 2 | 2019 | 177 | 0.180 |
Why?
| Carboplatin | 1 | 2021 | 140 | 0.180 |
Why?
| Heterografts | 1 | 2021 | 129 | 0.180 |
Why?
| Necrosis | 2 | 2019 | 229 | 0.170 |
Why?
| Drug Administration Schedule | 3 | 2017 | 751 | 0.170 |
Why?
| Hospitals, University | 1 | 2021 | 176 | 0.170 |
Why?
| Fatigue | 2 | 2022 | 317 | 0.170 |
Why?
| Immunotherapy | 2 | 2023 | 587 | 0.170 |
Why?
| Histone Deacetylases | 1 | 2022 | 210 | 0.170 |
Why?
| Clinical Trials as Topic | 3 | 2016 | 993 | 0.170 |
Why?
| Male | 13 | 2021 | 62858 | 0.170 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 58 | 0.170 |
Why?
| Benzodiazepines | 1 | 2021 | 129 | 0.170 |
Why?
| Immune System | 1 | 2021 | 176 | 0.160 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 115 | 0.160 |
Why?
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2019 | 43 | 0.160 |
Why?
| Kaplan-Meier Estimate | 1 | 2021 | 853 | 0.160 |
Why?
| Tumor Cells, Cultured | 1 | 2020 | 930 | 0.150 |
Why?
| Albumins | 1 | 2019 | 101 | 0.150 |
Why?
| Maintenance Chemotherapy | 1 | 2018 | 22 | 0.150 |
Why?
| Aquaporin 4 | 1 | 2019 | 96 | 0.150 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2018 | 500 | 0.150 |
Why?
| Aminopyridines | 1 | 2018 | 96 | 0.150 |
Why?
| Nausea | 1 | 2018 | 107 | 0.150 |
Why?
| Antibodies, Bispecific | 1 | 2018 | 49 | 0.140 |
Why?
| Mice, Inbred BALB C | 1 | 2020 | 1228 | 0.140 |
Why?
| Drug Therapy, Combination | 1 | 2020 | 1009 | 0.140 |
Why?
| Breast | 1 | 2018 | 152 | 0.140 |
Why?
| Radiotherapy, Adjuvant | 1 | 2018 | 209 | 0.140 |
Why?
| Purines | 1 | 2018 | 169 | 0.140 |
Why?
| Benzimidazoles | 1 | 2018 | 157 | 0.140 |
Why?
| Mastectomy | 1 | 2018 | 131 | 0.140 |
Why?
| Imidazoles | 1 | 2018 | 226 | 0.140 |
Why?
| Topotecan | 1 | 2017 | 12 | 0.140 |
Why?
| Isoflavones | 1 | 2017 | 25 | 0.140 |
Why?
| Calcium-Binding Proteins | 1 | 2018 | 210 | 0.140 |
Why?
| Survival Analysis | 1 | 2020 | 1263 | 0.140 |
Why?
| Carbolines | 1 | 2017 | 27 | 0.140 |
Why?
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 19 | 0.140 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2019 | 228 | 0.130 |
Why?
| Inhibitory Concentration 50 | 2 | 2016 | 81 | 0.130 |
Why?
| Nanoparticles | 1 | 2021 | 368 | 0.130 |
Why?
| Neoplasms, Radiation-Induced | 1 | 2016 | 71 | 0.130 |
Why?
| Cell Survival | 1 | 2019 | 1077 | 0.130 |
Why?
| Insulin-Like Growth Factor I | 1 | 2018 | 307 | 0.130 |
Why?
| Hypertension | 2 | 2018 | 1235 | 0.130 |
Why?
| GPI-Linked Proteins | 1 | 2016 | 67 | 0.130 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 391 | 0.120 |
Why?
| Neoplasms, Second Primary | 1 | 2016 | 108 | 0.120 |
Why?
| Tumor Protein p73 | 1 | 2015 | 14 | 0.120 |
Why?
| Antibodies, Neoplasm | 1 | 2015 | 35 | 0.120 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 1045 | 0.120 |
Why?
| Phosphorylation | 1 | 2019 | 1681 | 0.120 |
Why?
| Risk Reduction Behavior | 1 | 2016 | 209 | 0.120 |
Why?
| Hodgkin Disease | 1 | 2016 | 134 | 0.120 |
Why?
| Retrospective Studies | 3 | 2021 | 14454 | 0.120 |
Why?
| Maytansine | 1 | 2014 | 16 | 0.110 |
Why?
| Demography | 1 | 2015 | 277 | 0.110 |
Why?
| Brain Edema | 1 | 2014 | 60 | 0.110 |
Why?
| Drug Interactions | 1 | 2015 | 357 | 0.110 |
Why?
| Survival Rate | 2 | 2019 | 1869 | 0.110 |
Why?
| Protein Kinases | 1 | 2015 | 309 | 0.110 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2019 | 1356 | 0.110 |
Why?
| Sulfones | 1 | 2014 | 108 | 0.110 |
Why?
| Threonine | 1 | 2013 | 44 | 0.110 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 168 | 0.100 |
Why?
| Glycine | 1 | 2014 | 164 | 0.100 |
Why?
| Analgesics, Opioid | 1 | 2021 | 887 | 0.100 |
Why?
| Tumor Stem Cell Assay | 1 | 2012 | 32 | 0.100 |
Why?
| Time Factors | 2 | 2020 | 6482 | 0.100 |
Why?
| Drug Design | 1 | 2013 | 154 | 0.100 |
Why?
| Methionine | 1 | 2013 | 157 | 0.100 |
Why?
| Heterozygote | 1 | 2013 | 267 | 0.100 |
Why?
| Disease-Free Survival | 1 | 2014 | 647 | 0.100 |
Why?
| Treatment Failure | 1 | 2013 | 339 | 0.100 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2013 | 313 | 0.100 |
Why?
| Neovascularization, Pathologic | 1 | 2013 | 290 | 0.090 |
Why?
| Computational Biology | 1 | 2015 | 598 | 0.090 |
Why?
| Cluster Analysis | 1 | 2012 | 478 | 0.090 |
Why?
| Cell Transformation, Neoplastic | 1 | 2013 | 325 | 0.090 |
Why?
| Risk Assessment | 1 | 2020 | 3232 | 0.090 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 221 | 0.090 |
Why?
| Carcinoma in Situ | 1 | 2011 | 45 | 0.090 |
Why?
| Cellular Senescence | 1 | 2012 | 173 | 0.090 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 81 | 0.090 |
Why?
| Colorado | 1 | 2020 | 4375 | 0.090 |
Why?
| Mutation | 2 | 2012 | 3689 | 0.080 |
Why?
| Sequence Analysis, DNA | 1 | 2013 | 771 | 0.080 |
Why?
| Tumor Burden | 1 | 2010 | 283 | 0.080 |
Why?
| Brain Neoplasms | 2 | 2019 | 1163 | 0.080 |
Why?
| Pregnancy Trimester, Second | 1 | 2009 | 78 | 0.080 |
Why?
| Keratinocytes | 1 | 2010 | 243 | 0.080 |
Why?
| Mastectomy, Segmental | 1 | 2009 | 85 | 0.080 |
Why?
| Pregnancy Trimester, First | 1 | 2009 | 138 | 0.080 |
Why?
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 90 | 0.080 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2009 | 182 | 0.080 |
Why?
| Lymph Node Excision | 1 | 2009 | 165 | 0.070 |
Why?
| Risk | 1 | 2009 | 853 | 0.070 |
Why?
| Infusions, Intravenous | 2 | 2019 | 385 | 0.070 |
Why?
| Cell Adhesion Molecules | 2 | 2019 | 172 | 0.070 |
Why?
| Risk Factors | 1 | 2020 | 9704 | 0.070 |
Why?
| Prognosis | 2 | 2018 | 3772 | 0.070 |
Why?
| Gene Expression Profiling | 1 | 2012 | 1688 | 0.060 |
Why?
| Cell Cycle Proteins | 2 | 2023 | 577 | 0.060 |
Why?
| Antigens, Neoplasm | 2 | 2019 | 309 | 0.060 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2023 | 846 | 0.060 |
Why?
| Cell Cycle | 2 | 2018 | 581 | 0.060 |
Why?
| Combined Modality Therapy | 2 | 2019 | 1204 | 0.050 |
Why?
| Mesylates | 1 | 2022 | 7 | 0.050 |
Why?
| Signal Transduction | 2 | 2014 | 4826 | 0.050 |
Why?
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 64 | 0.050 |
Why?
| Clinical Protocols | 1 | 2023 | 252 | 0.050 |
Why?
| Ligands | 1 | 2024 | 614 | 0.050 |
Why?
| RNA, Small Interfering | 1 | 2024 | 571 | 0.050 |
Why?
| Chimerism | 1 | 2021 | 29 | 0.050 |
Why?
| Lymphoid Tissue | 1 | 2021 | 68 | 0.040 |
Why?
| Lymphocyte Subsets | 1 | 2021 | 85 | 0.040 |
Why?
| Liver | 1 | 2009 | 1826 | 0.040 |
Why?
| Mice, SCID | 1 | 2021 | 350 | 0.040 |
Why?
| SEER Program | 1 | 2021 | 206 | 0.040 |
Why?
| Hormones | 1 | 2020 | 140 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2021 | 586 | 0.040 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 24 | 0.040 |
Why?
| Tissue Distribution | 1 | 2018 | 291 | 0.040 |
Why?
| Infant, Newborn | 1 | 2009 | 5687 | 0.040 |
Why?
| Anemia | 1 | 2019 | 160 | 0.040 |
Why?
| Pregnancy | 1 | 2009 | 6357 | 0.030 |
Why?
| Cetuximab | 1 | 2016 | 93 | 0.030 |
Why?
| Retreatment | 1 | 2016 | 69 | 0.030 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 114 | 0.030 |
Why?
| Neoplasm Transplantation | 1 | 2016 | 258 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2016 | 195 | 0.030 |
Why?
| Platinum | 1 | 2016 | 44 | 0.030 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 572 | 0.030 |
Why?
| Transcription Factors | 1 | 2023 | 1628 | 0.030 |
Why?
| History, Ancient | 1 | 2015 | 52 | 0.030 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 258 | 0.030 |
Why?
| Databases, Genetic | 1 | 2015 | 228 | 0.030 |
Why?
| DNA Damage | 1 | 2017 | 364 | 0.030 |
Why?
| Mice, Knockout | 1 | 2021 | 2755 | 0.030 |
Why?
| Biomarkers | 2 | 2016 | 3880 | 0.030 |
Why?
| Opioid-Related Disorders | 1 | 2021 | 480 | 0.030 |
Why?
| Phenotype | 1 | 2021 | 3044 | 0.020 |
Why?
| Drug Combinations | 1 | 2013 | 323 | 0.020 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 253 | 0.020 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 431 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2016 | 1664 | 0.020 |
Why?
| Biopsy, Needle | 1 | 2011 | 188 | 0.020 |
Why?
| Cohort Studies | 1 | 2021 | 5388 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2014 | 809 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2017 | 1404 | 0.020 |
Why?
| HT29 Cells | 1 | 2010 | 36 | 0.020 |
Why?
| Proto-Oncogene Proteins | 1 | 2014 | 634 | 0.020 |
Why?
| ErbB Receptors | 1 | 2013 | 601 | 0.020 |
Why?
| Protein-Tyrosine Kinases | 1 | 2013 | 430 | 0.020 |
Why?
| Ki-67 Antigen | 1 | 2010 | 107 | 0.020 |
Why?
| Patient Selection | 1 | 2013 | 663 | 0.020 |
Why?
| Capillary Permeability | 1 | 2010 | 131 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2018 | 4892 | 0.020 |
Why?
| Patient Satisfaction | 1 | 2013 | 641 | 0.020 |
Why?
| Membrane Proteins | 1 | 2015 | 1105 | 0.020 |
Why?
| Positron-Emission Tomography | 1 | 2010 | 283 | 0.020 |
Why?
| Algorithms | 1 | 2015 | 1618 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2019 | 3376 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2016 | 2523 | 0.020 |
Why?
| Adolescent | 1 | 2024 | 20179 | 0.010 |
Why?
| Brain | 1 | 2014 | 2620 | 0.010 |
Why?
| Young Adult | 1 | 2014 | 12312 | 0.010 |
Why?
|
|
Diamond's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|